8-KLeadership ChangesRegulation FD

DEXCOM INC 8-K Report, Executive Changes (Feb 27, 2008)

Filed February 27, 2008For Securities:DXCM

Summary

This Form 8-K filing from DexCom, Inc. (DXCM), dated February 27, 2008, details two key events: the approval of a 2008 bonus plan for management and select employees, and the promotion of Andrew K. Balo to Senior Vice President of Clinical and Regulatory Affairs and Quality Assurance. The bonus plan is designed to incentivize the achievement of specific revenue and performance milestones, with bonus payouts directly tied to the company's success in these areas. This structure suggests a focus on driving top-line growth and operational execution in the upcoming fiscal year. The promotion of Mr. Balo to a senior leadership role in a critical area like clinical and regulatory affairs and quality assurance signals a commitment to advancing these functions within the company. Investors should view these developments as indicators of management's strategic priorities and their approach to incentivizing performance and strengthening key operational departments during this period.

Key Highlights

  • 1DexCom approved a 2008 bonus plan for management and select employees, including the CEO and CFO.
  • 2Bonus payouts are contingent upon achieving specified fiscal 2008 revenue goals and performance milestones.
  • 3The bonus plan is structured with a 70% weighting towards revenue targets and 30% towards performance milestones.
  • 4CEO's target bonus is 50% of base salary; Senior Vice Presidents' target bonus is 35% of base salary.
  • 5Minimum revenue targets must be met for any portion of the revenue-based bonus to be paid.
  • 6A separate bonus plan was approved for the Vice President of Sales, with a maximum bonus of 50% of base salary, also tied to revenue and performance targets.
  • 7Andrew K. Balo was promoted to Senior Vice President of Clinical and Regulatory Affairs and Quality Assurance.

Frequently Asked Questions

The primary purpose of the 2008 bonus plan is to incentivize and reward management and select individual contributors, including key executive officers, for achieving specified performance targets, specifically revenue goals and other operational milestones, during fiscal year 2008.

Bonus payouts are determined by a combination of achieving annual revenue goals (70% of the bonus) and meeting certain performance milestones (30% of the bonus). There are specific conditions, such as meeting a minimum revenue target, before any revenue component of the bonus can be paid.

The promotion of Andrew K. Balo to Senior Vice President of Clinical and Regulatory Affairs and Quality Assurance suggests DexCom is strengthening its leadership in these crucial areas. This can be viewed positively by investors as it indicates a focus on ensuring compliance, advancing product development through regulatory pathways, and maintaining quality standards, which are vital for a medical device company.

Yes, there are specific targets. A minimum revenue target must be achieved for any Revenue Component bonus to be paid. Upon achieving 100% of the revenue target, participants receive 100% of their targeted Revenue Component. Exceeding the target can result in bonuses up to 175% of the targeted Revenue Component. Performance milestones are also set, with 25% of the targeted Performance Component paid for each of four milestones achieved.